Our team strives to advance medicines for neurological,
neuroendocrine, and neuropsychiatric disorders.
We relentlessly pursue scientific discovery and development that can lead to important therapies for patients who desperately need new, better options.
Congenital Adrenal Hyperplasia
crinecerfont for congenital adrenal hyperplasia (CAH)
Crinecerfont is an investigational, oral, non-steroidal, selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist for the potential treatment of CAH due to 21-hydroxylase deficiency (21-OHD) in children and adults.
NBI-1065845§ for inadequate response to treatment in major depressive disorder (MDD)
NBI-1065845§ is a potential first-in-class, investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator for the potential treatment of patients with inadequate response to treatment in MDD.
luvadaxistat§ for cognitive impairment associated with schizophrenia (CIAS)
Luvadaxistat§ is a potential first-in-class, investigational, selective d-amino acid oxidase (DAAO) inhibitor for the potential treatment of cognitive impairment associated with schizophrenia (CIAS).
NBI-1070770§ for major depressive disorder (MDD)
Neurocrine Biosciences has initiated a Phase 1 clinical study with NBI-1070770§, a novel, orally active, small molecule as a potential treatment for major depressive disorder.
*Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and other select Asian markets.
†Licensed from Idorsia Ltd.
‡Licensed from Xenon Pharmaceuticals, Inc.
§Licensed from Takeda Pharmaceutical Company Limited.
¶Licensed from Sosei Heptares.